Efficacy and Safety of ICP-332 Versus Placebo in Participants With Moderate to Severe Plaque Psoriasis

Inclusion criteria

• Subjects voluntarily participate in this study and have signed the Informed Consent Form (ICF).
• Male or female subjects aged ≥ 18 years and ≤ 70 years
• A history of plaque psoriasis for ≥6 months at baseline
• Meet the following three criteria:

• Psoriasis Area and Severity Index (PASI) score ≥12
• Static Physician's Global Assessment (sPGA) score ≥3
• Psoriasis affected Body Surface Area (BSA) ≥10%
• The subject requires systemic treatment and/or phototherapy.

Exclusion criteria

• Diagnosed with non-plaque psoriasis.
• Subject had laboratory values meeting any of the protocol-specified criteria at Screening.
• Presence of clinically serious, progressive, or uncontrolled disease.
• Previous history of alcoholism or drug abuse (except for those who have been completely abstinent for more than 6 months before randomization).
• Pregnant or lactating women.
• The investigator accepts ICP-332 for any reason that the subject is not suitable for this study.